Pliant Therapeutics to Participate in Piper Sandler Lung Day
Pliant Therapeutics (Nasdaq: PLRX) announced that CEO Bernard Coulie will participate in a virtual fireside chat during Piper Sandler Lung Day on October 15, 2021, at 11:00 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pliant Therapeutics (Nasdaq: PLRX) announced that CEO Bernard Coulie will participate in a virtual fireside chat during Piper Sandler Lung Day on October 15, 2021, at 11:00 a.m. ET. This event will focus on the company's efforts in developing novel therapeutics for fibrosis, particularly its lead candidate, PLN-74809, which targets idiopathic pulmonary fibrosis and primary sclerosing cholangitis. A replay of the chat will be available on Pliant's website for 90 days post-event.
Details
News Market Reaction – PLRX
The recorded move for PLRX in the trading session of this news was +2.41%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer, will participate in a virtual fireside chat as part of the Piper Sandler Lung Day on Friday, October 15, 2021, at 11:00 a.m. ET.
A replay of the Piper Sandler virtual fireside chat will be available on the Events & Presentations page of Pliant’s website following the conclusion of the event for 90 days.
About Pliant Therapeutics, Inc.
Pliant is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting Phase 2a trials of PLN-74809 in the lead indications of IPF and PSC. Pliant has also developed PLN-1474, a small-molecule selective inhibitor of αvß1 for the treatment of nonalcoholic steatohepatitis, or NASH with liver fibrosis, which Pliant has transferred to Novartis pursuant to its development partnership. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies. For additional information about Pliant, visit www.pliantrx.com and follow us on Twitter, LinkedIn, Facebook, and YouTube.
Investor and Media Contact:
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.